Products

What will AGI do for Acitazanolast?

This classification denotes an anti-asthmatic agent with the molecular formula C9H7N5O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 99Y8VJ356G, chemically known as oxanilic acid, 3-(1h-tetrazol-5-yl)- but generally known as acitazanolast, which bears US NIH Compound Identifier 2006. Acitazanolast comes in base and hydrate forms. European Medicines Agency schedules Acitazanolast in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05238MIG. The term ACITAZANOLAST is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 9, No. 3, 1995, List 35). ACITAZANOLAST is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule acitazanolast under HS 29339990 and SITC 51577. As of Q4 2014, ACITAZANOLAST remains the US FDA Preferred Term for this commodity. Acitazanolast bears US NLM identifiers UMLS ID C0642373 and NCI Concept Code C74133. SMILES: O=C(NC1CC(CCC1)C1N[NH]NN1)C(=O)O.

How AGI delivers it

Four ways AGI delivers for Acitazanolast

  • Headless SaaS for Agents

    Give your tools an agent-consumable surface (API / MCP / SDK) so agents can do the work.

    For Acitazanolast, give your tools an agent-consumable surface (API / MCP / SDK) so agents can do the work.

  • Services-as-Software

    Get the professional outcome delivered as software, priced on results, not headcount.

    For Acitazanolast, get the professional outcome delivered as software, priced on results, not headcount.

Value flow

How Acitazanolast connects

measured by

  • Assay Puritymodel
  • Heavy Metalsmodel
  • Related Substancesmodel
  • Residual Solventsmodel